Researchers are unveiling new immunotherapy strategies that activate the immune system's most powerful cancer-fighting cells, with early results showing significant benefit for melanoma patients who have exhausted other treatment options. Two investigational therapies designed to selectively boost CD8+ T cells, the immune cells that drive antitumor responses, are showing encouraging efficacy in patients with advanced melanoma that has resisted checkpoint inhibitor therapy.

What Are CD8-Targeted Immunotherapies and How Do They Work?

CD8+ T cells are specialized immune cells that hunt down and destroy cancer cells. Traditional immunotherapy drugs like checkpoint inhibitors work by removing the brakes on these cells, but they activate the entire immune system broadly, which can cause significant side effects. The new approach is more precise: it delivers immune-boosting signals directly to CD8+ T cells while avoiding other immune cells that can cause toxicity or interfere with treatment.

Asher Biotherapeutics is developing two drugs using this strategy. AB248 is a CD8-targeted interleukin-2 (IL-2) therapy, while AB821 is a CD8-targeted interleukin-21 (IL-21) therapy. Both are designed to selectively activate CD8+ T cells without triggering the dangerous side effects associated with high-dose systemic cytokine therapy, such as capillary leak syndrome, a condition where fluid leaks from blood vessels into surrounding tissues.

What Results Are Researchers Seeing in Clinical Trials?

AB248 demonstrated robust CD8+ T cell expansion of approximately 20-fold at higher dose levels without causing vascular leak or capillary leak syndrome, a major distinction from traditional high-dose IL-2 therapy. In patients with melanoma that had progressed despite checkpoint inhibitor treatment, AB248 monotherapy achieved an 18% objective response rate (meaning tumors shrank by at least 30%) in patients with cutaneous melanoma. When combined with pembrolizumab, a checkpoint inhibitor, the response rate improved to 30% in patients treated at the optimal dose level.

Notably, responses were observed across different melanoma subtypes, including cutaneous melanoma and more difficult-to-treat forms such as mucosal and acral melanoma. The most common side effects were grade 1 or 2 (mild to moderate) and self-limited, meaning they resolved on their own.

A second approach, OBX-115, is an engineered tumor-infiltrating lymphocyte (TIL) cell therapy developed by Obsidian Therapeutics. This treatment involves extracting immune cells from a patient's own tumor, expanding them in the laboratory, and reinfusing them with additional immune support. OBX-115 achieved a 67% objective response rate in 15 patients with advanced melanoma that had progressed after checkpoint inhibitor therapy. Importantly, 80% of the responses were ongoing at the time of analysis, suggesting durable benefit.

"These data are particularly encouraging given that patients enrolled in the melanoma cohorts had received extensive prior immunotherapy, including prior checkpoint inhibitor doublets," said Harriet Kluger, M.D., Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology at Yale School of Medicine.

Harriet Kluger, M.D., Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology at Yale School of Medicine

How Do These Therapies Differ From Current Treatment Options?

Current melanoma treatments often require intensive medical support. OBX-115 offers a notably different patient experience compared to traditional cell therapies. The treatment can use tissue obtained through a minimally invasive core needle biopsy rather than surgical tumor removal. It also uses low-dose lymphodepletion (a temporary reduction in immune cells to make room for the infused cells) that is compatible with outpatient administration, and it eliminates the need for interleukin-2 (IL-2) supplementation during treatment.

In the trial, all 15 patients received low-dose lymphodepletion, with 4 patients treated entirely in the outpatient setting. Critically, there were no dose-limiting toxicities, no treatment-related deaths, no immune effector cell-associated neurotoxicity syndrome (ICANS, a serious neurological complication), and no ICU transfers. The majority of treatment-related side effects were grade 2 or less.

What Makes These Approaches Promising for Difficult-to-Treat Melanoma?

The patient populations in these trials represent some of the most challenging cases in oncology. In the OBX-115 study, 93% of patients had been previously treated with checkpoint inhibitor doublets (two checkpoint inhibitors combined), and 73% had disease progression specifically after anti-PD-1 plus anti-CTLA-4 combination therapy. These patients typically have very low response rates to subsequent therapies, making the 67% response rate particularly noteworthy.

• Checkpoint Inhibitor Resistance: Both therapies showed activity in patients whose melanoma had progressed despite prior checkpoint inhibitor treatment, addressing a major unmet need in oncology.
• Favorable Safety Profile: AB248 achieved significant CD8+ T cell expansion without capillary leak syndrome, and OBX-115 showed no dose-limiting toxicities or ICU transfers, reducing treatment burden compared to traditional approaches.
• Durable Responses: OBX-115 demonstrated that 80% of responses were ongoing at median follow-up of 4.3 months, suggesting sustained clinical benefit rather than temporary tumor shrinkage.
• Broad Melanoma Coverage: AB248 showed activity across cutaneous, mucosal, and acral melanoma subtypes, expanding potential applicability beyond the most common form of the disease.

What Are the Next Steps for These Therapies?

Both programs are advancing toward larger clinical trials. Asher Biotherapeutics is also evaluating AB248 in combination with tarlatamab, a different type of immunotherapy, in patients with extensive-stage small cell lung cancer. The company is exploring whether AB248 and AB821 can be used together to deepen and extend antitumor responses while maintaining tolerability.

Obsidian Therapeutics has reached alignment with the FDA on key design elements for a registration-enabling trial and plans to begin treating patients in the pivotal cohort in mid-2026. The company is also investigating OBX-115 in patients with non-small cell lung cancer, with phase 1 data expected in the first half of 2027.

"Results from the Agni-01 study, including the 67% ORR, with 80% of responses ongoing as of the median 4.3 month study follow up, further emphasize OBX-115's potential in advanced melanoma," said Parameswaran Hari, M.D., M.S., Chief Medical Officer of Obsidian.

Parameswaran Hari, M.D., M.S., Chief Medical Officer of Obsidian

These emerging therapies represent a shift toward more targeted, precise immunotherapy approaches that harness the power of CD8+ T cells while minimizing systemic toxicity. For melanoma patients who have exhausted conventional options, these results offer meaningful hope for durable disease control with improved quality of life during treatment.